Anti-HLA antibody ligation to HLA class I molecules expressed by endothelial cells stimulates tyrosine phosphorylation, inositol phosphate generation, and proliferation

Human Immunology

Volumn 53, Issue 1, 1997, Pages 90-97

  Bian, Hong ^a   Harris, Paul E ^a   Mulder, Arend ^b   Reed, Elaine F ^a  

^a Columbia University ^*  (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIBODY; HLA ANTIGEN CLASS 1; INOSITOL PHOSPHATE;

ALLOTRANSPLANTATION; ANTIGEN BINDING; ARTICLE; ENDOTHELIUM CELL; GRAFT OCCLUSION; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; LYMPHOCYTE PROLIFERATION; PHOSPHOINOSITIDE METABOLISM; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

EID: 0030888601     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0198-8859(96)00272-8     Document Type: Article

References (48)

1. Hosenpud JD, Novick RJ, Breen TJ, Daily OP: The registry of the International Society for Heart and Lung Transplantation: eleventh official report-1994. J Heart Lung Transplant 13:561, 1994.
2. Terasaki PI, Yuge J, Cecka JM, Gjerston DW, Takemoto S, Cho Y: Thirty-year trends in clinical kidney transplantation. In Terasaki PI, Cecka JM (eds): Clinical Transplants 1993. UCLA Tissue Typing Laboratory, Los Angeles, CA, 1993.
3. Azuma H, Tilney NL: Chronic graft rejection. Curr Opin Immunol 6:770, 1994.
4. Hayry P, Mennander A, Yilmaz S, Ustinov J, Raisanen A, Miettinen A, Lautenschlager I, Lemstrom K, Bruggeman CA, Paavonen T: Towards understanding the pathophysiology of chronic rejection. Clin Investig 70:780, 1992.
5. Tilney NL, Whitley WD, Diamond JR, Kupiec-Weglinski JW, Adams DH: Chronic rejection: an undefined conundrum. Transplantation 52:389, 1991.
6. Paul LC, Fellstrom B: Chronic vascular rejection of the heart and the kidney: have rational treatment options emerged? Transplantation 53:1169, 1992.
7. Rekhter MD, Gordon D. Active proliferation of different cell types, including lymphocytes in human atherosclerotic plaques. Am J Pathol 147:668, 1995.
8. Hess HL, Hastilo A, Mohanakumar T, Cowley MJ, Vetrovac G, Szentpetery S, Wolfgang TC, Lower RR: Accelerated atherosclerosis in cardiac transplantation: role of cytotoxic B-cell antibodies and hyperlipidemia. Circulation 68:94, 1983.
9. Halloran PF, Schlaut J, Solez K, Srinivasa N: The significance of the anti-class I response II: clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation 5:550, 1992.
10. O'Connel TX, Mobray JF: Arterial intimai thickening produced by alloantibody and xenoantibody. Transplantation 51:262, 1973.
11. Fenoglio J, Ho E, Reed E, Rose EA, Smith C, Reemstma K, Marobe C, Suciu-Foca N: Anti-HLA antibodies and heart allograft survival. Transplant Proc 21:807, 1989.
12. Suciu-Foca N, Reed E, D'Agati VD, Ho E, Cohen DJ, Benvenisty AI, McCabe R, Brensilver JM, King DW, Hardy MA: Soluble HLA-antigens, anti-HLA antibodies and anti-idiotypic antibodies in the circulation of renal transplant recipients. Transplantation 51:593, 1991.
13. Suciu-Foca N, Reed E, Marboe C, Xi YP, Sun YK, Ho E, Rose EA, Reemstma K, King DW. Role of anti-HLA antibodies in heart transplantation. Transplantation 51:716, 1991.
14. Cherry R, Nielsen H, Reed E, Reemstma K, Suciu-Foca N, Marboe CC: Vascular (humoral) rejection in cardiac allograft biopsies: relation to circulating anti-HLA antibodies. J Heart Lung Transplant 11:24, 1992.
15. Barr M, Cohen DJ, Benvenisty AI, Hardy M, Reemtsma K, Rose EA, Marboe C, D'Agati V, Suciu-Foca N, Reed E, Ramey W: Effect of anti-HLA antibodies on long-term survival of heart and kidney allografts. Transplant Proc. 25:262, 1993.
16. Reed EF, Hong B, Ho E, Harris PE, Weinberger J, Suciu-Foca N: Monitoring of soluble HLA alloantigens and anti-HLA antibodies identifies heart allograft recipients at risk of transplant associated coronary artery disease. Transplantation 61:1, 1996.
17. Tscherning T, Claesson M: Signal transduction via MHC class-I molecules in T cells. Scand J Immunol 39:117, 1994.
18. Geppert TD, Davis LS, Gur H, Wacholtz MC, Lipsky PE. Accessory cell signals involved in T-cell activation. Immunol Rev 117:5, 1990.
19. Dasgupta JD, Egea E, Relias V, Iglesias A, Gladstone P, Yunis EJ: Involvement of major histocompatibility complex class I antigens in T cell activation. Eur J Immunol 20:1553, 1990.
20. Dissing S, Geisler C, Rubin B, Plesner T, Claesson MH: T cell activation II: activation of human T lymphoma cells by cross-linking of their MHC class I antigens. Cell Immunol 126:196, 1990.
21. Wacholtz MC, Patel SS, Lipsky PE: Patterns of costimulation of T cell clones by cross-linking CD3, CD4/CD8, and class I MHC molecules. J Immunol 142:4201, 1989.
22. Geppert TD, Wacholtz MC, Davis LS, Lipsky PE: Activation of human T4 cells by cross-linking class 1 MHC molecules. J Immunol 140:2155, 1988.
23. Geppert TD, Lipsky PE: Association of various T cell-surface molecules with the cytoskeleton effect of cross-linking and activation. J Immunol 146:3298, 1991.
24. Sambhara SR, Miller RG: Programmed cell death of T cells signaled by the T cell receptor and the alpha 3 domain of class I MHC. Science 252:1424, 1991.
25. Taylor DS, Nowell PC, Kornbluth J: Anti-HLA class I antibodies inhibit the T cell-independent proliferation of human B lymphocytes. J Immunol 139:1792, 1987.
26. Skov S, Odum N, Claesson MH: MHC class I signaling in T cells leads to tyrosine kinase activity and PLC-γ1 phosphorylation. J Immunol 154:1167, 1995.
27. Gilliand LK, Norris NA, Grosmaire LS, Ferrone S, Gladstone, P, Ledbetter JA: Signal transduction in lymphocyte activation through cross-linking of HLA class I molecules. Hum Immunol 25:269, 1989.
28. Lassalle P, LaGrou C, Delneste Y, Sanceau J, Coll J, Torpier G, Wietzerbin J, Stehelin D, Tonnel AB, Capron A: Human endothelial cells transfected by SV40 T antigens: characterization and potential use as a source of normal endothelial factors. Eur J Immunol 22:425, 1992.
29. Decker SJ, Harris PE: Effects of platelet-derived growth factor on phosphorylation of the epidermal growth factor receptor in human skin fibroblasts. J Biol Chem 264:9204, 1989.
30. Berridge MJ: Inositol trisphosphate and calcium signalling. Nature 361:315, 1993.
31. Salomon RN, Hughes CCW, Schoen FJ, Payne DD, Pober JS, Libby P: Human coronary transplantation associated arteriosclerosis: evidence for a chronic immune reaction to activated graft endothelial cells. Am J Pathol 138:791, 1991.
32. Narrod J, Kormos R, Armitage J, Hardesty R, Ladowski J, Griffith B: Acute rejection and coronary artery disease in long-term survivors of heart transplantation. J Heart Transplant 8:418, 1989.
33. Almond PS, Matas A, Gillingham K, Dunn DL, Payne WD, Gores P, Gruzssner R, Najarian JS: Risk factors for chronic rejection in renal allograft recipients. Transplantation 55:752, 1993.
34. Hosenpud JD, Morris TE, Shipley GD, Mauck KA, Wagner CR: Cardiac allograft vasculopathy: preferential regulation of endothelial cell-derived mesenchymal growth factors in response to a donor-specific cell-mediated allogeneic response. Transplantation 61:939, 1996.
35. Markus BH, Colson YL, Fung JJ, Zeevi A, Duquesnoy RJ: HLA antigen expression on cultured human arterial endothelial cells. Tissue Antigens 32:241, 1988.
36. Guardiola J, Maffei A: Control of MHC class II gene expression in autoimmune, infectious, and neoplastic diseases. Crit Rev Immunol 13:247, 1993.
37. Hosenpud JD, Shipley GD, Morris TE, Hefeneider SH, Wagner CR: The modulation of human aortic endothelial cell ICAM-1 (CD-54) expression by serum containing high titers of anti-HLA antibodies. Transplantation 55:405, 1993.
38. Shingu M, Hashimoto Y, Johnson AR, Hurd ER: The search for Fc receptors on human tissues and human endothelial cells in culture. Proc Soc Exp Biol Med 167:147, 1981.
39. Hunter T, Cooper JA: Protein-tyrosine kinases. Annu Rev Biochem 54:897, 1985.
40. Gur H, El-Zaatari F, Geppert TD, Wacholtz MC, Taurog JD, Lipsky PE: Analysis of T cell signaling by class I MHC molecules: the cytoplasmic domain is not required for signal transduction. J Exp Med 172:1267, 1990.
41. Due C, Simonsen M, Olsson L: The major histocompatibility complex class I heavy chain as a structural subunit of the human cell membrane insulin receptor: implications for the range of biologic functions of histocompatibility antigens. Proc Natl Acad Sci USA 83:6007, 1986
42. Phillips ML, Moule ML, Delovitch TL, Yip CC: Class I histocompatibility antigens and insulin receptors: evidence for interactions. Proc Natl Acad Sci USA 83:3474, 1986.
43. Samson M, Cousin JL, Fehlmann M: Cross-linking of insulin receptors to MHC antigens in human B lymphocytes: evidence for selective molecular interactions. J Immunol 137:2293, 1986.
44. Hansen T, Stagsted J, Pedersen L, Roth RA, Goldstein A, Olsson L: Inhibition of insulin receptor phosphorylation by peptides derived from major histocompatibility complex class I antigens. Proc Natl Acad Sei USA 86:3123, 1989.
45. Stagsted J, Reaven GM, Hansen T, Goldstein A, Olsson L: Regulation of insulin receptor functions by a peptide derived from a major histocompatibility complex class I antigen. Cell 62:297, 1990.
46. Hsu D, Olefsky JM: Effect of a major histocompatibility complex class I peptide on insulin-like growth factor-I receptor internalization and biological signaling. Endocrinology 133:1247, 1993.
47. Schrieber AB, Schlessinger J, Edidin M: Interaction between major histocompatibility complex antigens and epidermal growth factor receptors on human cells. J Cell Biol 98:725, 1984.
48. Bregenholt S, Ropke M, Skov S, Claesson MH: Ligation of MHC class I molecules on peripheral blood T lymphocytes induces new phenotypes and functions. J Immunol 157:993, 1996.